(Source: Enanta Pharmaceuticals Inc) AbbVie reports 98 percent of previously untreatedgenotype 1b (GT1b) chronic hepatitis C virus (HCV) infected patients without cirrhosis achieved SVRin Phase 3b GARNET study First study evaluating 8 weeks of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets) GT1b is the most common HCV subtype globally, accounting for approximately 47 percent of the estimated nine million people infected with chronic HCV in Europe alone WATERTOWN, Mass.--(BUSINESS WIRE)--Sep. 23, 2016-- Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral...
↧